Overview on advance therapt technology: Chimeric antigen receptor (CAE)T celltherapy
Article Sidebar
Published:
Aug 15, 2018
Main Article Content
Article Details
How to Cite
1.
วิริยะบัญชา ว. Overview on advance therapt technology: Chimeric antigen receptor (CAE)T celltherapy. TFDJ [Internet]. 2018 Aug. 15 [cited 2024 Apr. 19];25(1):4-8. Available from: https://he01.tci-thaijo.org/index.php/fdajournal/article/view/140297
Section
Review Article
References
1.US Food and drug administration. (30 August 2017). FDA approval brings first gene therapy to the United States: CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia. FDA News release. [Retrieved from https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm]
2.Hartmann, J., Schüßler-Lenz, M., Bondanza, A., & Buchholz, C. J. (2017). Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts. EMBO Molecular Medicine, 9(9), 1183–1197.
3.Amadori, A., Zamarchi, R., Silvestro, G. D., Forza, G., Cavatton, G., Danieli, G. A., Chieco-Bianchi, L. (1995). Genetic control of the CD4/CD8 T-cell ratio in humans. Nature Medicine,1(12), 1279-1283.
4.Pennock, N. D., White, J. T., Cross, E. W., Cheney, E. E., Tamburini, B. A., & Kedl, R. M. (2013). T cell responses: naive to memory and everything in between. AJP: Advances in Physiology Education, 37(4), 273-283.
5.Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2013). Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunological Reviews, 257(1), 107-126.
6.Themeli, M., Rivière, I., & Sadelain, M. (2015). New Cell Sources for T Cell Engineering and Adoptive Immunotherapy. Cell Stem Cell, 16(4), 357-366.
7.Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017). Global Manufacturing of CAR T Cell Therapy. Molecular Therapy - Methods & Clinical Development, 4, 92-101.
8.George, B. (2011). Regulations and guidelines governing stem cell based products: Clinical considerations. Perspectives in Clinical Research, 2(3), 94-99.
9.US National cancer institute. (31 August 2017). CAR T cells: Engineering patients’ immune cells to treat their cancers. [Retrieved from https://www.cancer.gov/about-cancer/treatment/research/car-t-cells]
10.Yang, Y., Jacoby, E., & Fry, T. J. (2015). Challenges and opportunities of allogeneic donor-derived CAR T cells. Current Opinion in Hematology, 22(6), 509-515.
11.Hanna, E., Rémuzat, C., Auquier, P., & Toumi, M. (2016). Advanced therapy medicinal products: current and future perspectives. Journal of Market Access & Health Policy, 4(1), 31036.
2.Hartmann, J., Schüßler-Lenz, M., Bondanza, A., & Buchholz, C. J. (2017). Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts. EMBO Molecular Medicine, 9(9), 1183–1197.
3.Amadori, A., Zamarchi, R., Silvestro, G. D., Forza, G., Cavatton, G., Danieli, G. A., Chieco-Bianchi, L. (1995). Genetic control of the CD4/CD8 T-cell ratio in humans. Nature Medicine,1(12), 1279-1283.
4.Pennock, N. D., White, J. T., Cross, E. W., Cheney, E. E., Tamburini, B. A., & Kedl, R. M. (2013). T cell responses: naive to memory and everything in between. AJP: Advances in Physiology Education, 37(4), 273-283.
5.Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2013). Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunological Reviews, 257(1), 107-126.
6.Themeli, M., Rivière, I., & Sadelain, M. (2015). New Cell Sources for T Cell Engineering and Adoptive Immunotherapy. Cell Stem Cell, 16(4), 357-366.
7.Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017). Global Manufacturing of CAR T Cell Therapy. Molecular Therapy - Methods & Clinical Development, 4, 92-101.
8.George, B. (2011). Regulations and guidelines governing stem cell based products: Clinical considerations. Perspectives in Clinical Research, 2(3), 94-99.
9.US National cancer institute. (31 August 2017). CAR T cells: Engineering patients’ immune cells to treat their cancers. [Retrieved from https://www.cancer.gov/about-cancer/treatment/research/car-t-cells]
10.Yang, Y., Jacoby, E., & Fry, T. J. (2015). Challenges and opportunities of allogeneic donor-derived CAR T cells. Current Opinion in Hematology, 22(6), 509-515.
11.Hanna, E., Rémuzat, C., Auquier, P., & Toumi, M. (2016). Advanced therapy medicinal products: current and future perspectives. Journal of Market Access & Health Policy, 4(1), 31036.